# US 2017/0283387 A1 · Metabolism probes for therapy and diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283387 A1
- Document ID: US20170283387A1
- Status: Published application
- Kind: A1
- Application number: 15/510,217
- Filed: 2015-09-09
- Published: 2017-10-05
- Earliest claimed: 2014-09-09
- Assignees: Vanderbilt University
- Applicants: Vanderbilt University
- Inventors: H. Charles Manning; Michael Schulte
- Web page: https://patentgrep.com/patent/US20170283387A1

## CPC

- C07D 295/26: Sulfur atoms
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- C07C 237/04: the carbon skeleton being acyclic and saturated
- C07C 237/10: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07D 207/325: with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D 213/40: Acylated substituent nitrogen atom
- C07D 235/18: with aryl radicals directly attached in position 2
- C07D 277/66: with aromatic rings or ring systems directly attached in position 2
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Novel 2-substituted glutamylanides useful as modulators of ASCT2 inhibitors. Compounds of the present invention can be used to treat patients suffering from diseases caused or influenced by abnormal ASCT2 transporter dysfunction.

## Claims

### Claim 1

A compound of the following formula:
wherein:
R1 is a bond, optionally substituted C1-C6 alkyl, or optionally substituted SO2—(C1-C6 alkyl);
R2 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocycle, or optionally substituted heterocycloalkyl;
R3 is H or optionally substituted C1-C6 alkyl; and
R4 is NH2 or NHBoc;
or pharmaceutically acceptable salts or derivatives thereof.

### Claim 2 (depends on 1)

A compound of claim 1, wherein R1 is a bond, —CH2—, or —CH2—CH2—.

### Claim 3 (depends on 1)

A compound of claim 1, wherein R2 is optionally substituted phenyl.

### Claim 4 (depends on 1)

A compound of claim 1, wherein R2 is optionally substituted and chosen from morpholino, pyrrolidine, pyrrole, piperidine, pyridine, benzoimidizole, benzothiazole, piperizine, methyl-piperizine, or pyridine.

### Claim 5 (depends on 1)

A compound of claim 1, wherein R2 is chosen from:

### Claim 6 (depends on 1)

A compound of claim 1, wherein R3 is —H or

### Claim 7 (depends on 1)

A compound of claim 1, of the following formula:
or a pharmaceutically acceptable salt or derivative thereof.

### Claim 8 (depends on 1)

A method of modulating ASCT2 function in a patient in need thereof, comprising administering to the patient an effective ASCT2 function modulating amount of a compound of claim 1.

### Claim 9 (depends on 1)

A compound of one of claim 1 7 for use as a medicament.

### Claim 10 (depends on 1)

A compound of one claim 1 for use in the treatment of cancer.

### Claim 11 (depends on 10)

The compound of claim 10, wherein the cancer is lung, colon, and pancreas cancer.

### Claim 12 (depends on 1)

A method of modulating angiogenesis, tumor progression, and/or metastasis comprising the step of administering to a tissue or a subject associated with a disease condition a therapeutically effective amount of a compound of claim 1.

### Claim 13 (depends on 12)

The method of claim 12, where said modulating inhibits angiogenesis, tumor progression, and/or metastasis.

### Claim 14 (depends on 13)

The method of claim 13, wherein said inhibiting involves inhibiting cellular glutamine uptake via ASCT2.

### Claim 15 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A compound comprising:
a compound of claim 1 and an imaging agent coupled thereto.

### Claim 17 (depends on 16)

A compound of claim 16, wherein the imaging agent is a radionuclide.
